These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

361 related items for PubMed ID: 25081140

  • 1. The real impact of telaprevir dosage on the antiviral and side effects of telaprevir, pegylated interferon and ribavirin therapy for chronic hepatitis C patients with HCV genotype 1.
    Oze T, Hiramatsu N, Yakushijin T, Yamada R, Harada N, Morishita N, Oshita M, Mita E, Ito T, Inui Y, Inada M, Tamura S, Yoshihara H, Imai Y, Kato M, Miyagi T, Yoshida Y, Tatsumi T, Kasahara A, Hayashi N, Takehara T.
    J Viral Hepat; 2015 Mar; 22(3):254-62. PubMed ID: 25081140
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of telaprevir, pegylated interferon α-2b and ribavirin triple therapy in Japanese patients infected with hepatitis C virus genotype 1b.
    Kawaguchi Y, Iwane S, Kumagai T, Yanagita K, Yasutake T, Ide Y, Otsuka T, Eguchi Y, Ozaki I, Akiyama T, Kawazoe S, Mizuta T.
    Intern Med; 2015 Mar; 54(20):2551-60. PubMed ID: 26466688
    [Abstract] [Full Text] [Related]

  • 4. The prospective randomized study on telaprevir at 1500 or 2250 mg with pegylated interferon plus ribavirin in Japanese patients with HCV genotype 1.
    Oze T, Hiramatsu N, Yakushijin T, Yamada R, Harada N, Morishita N, Yamada A, Oshita M, Kaneko A, Suzuki K, Inui Y, Tamura S, Yoshihara H, Imai Y, Miyagi T, Yoshida Y, Tatsumi T, Kasahara A, Hayashi N, Takehara T.
    J Gastroenterol; 2015 Mar; 50(3):313-22. PubMed ID: 24806033
    [Abstract] [Full Text] [Related]

  • 5. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.
    McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, McNair L, Alam J, Muir AJ, PROVE1 Study Team.
    N Engl J Med; 2009 Apr 30; 360(18):1827-38. PubMed ID: 19403902
    [Abstract] [Full Text] [Related]

  • 6. Telaprevir-based triple therapy for chronic hepatitis C patients with advanced fibrosis: a prospective clinical study.
    Ogawa E, Furusyo N, Nakamuta M, Kajiwara E, Nomura H, Dohmen K, Takahashi K, Satoh T, Azuma K, Kawano A, Tanabe Y, Kotoh K, Shimoda S, Hayashi J, Kyushu University Liver Disease Study (KULDS) Group.
    Aliment Pharmacol Ther; 2013 Nov 30; 38(9):1076-85. PubMed ID: 24099469
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections.
    Foster GR, Hézode C, Bronowicki JP, Carosi G, Weiland O, Verlinden L, van Heeswijk R, van Baelen B, Picchio G, Beumont M.
    Gastroenterology; 2011 Sep 30; 141(3):881-889.e1. PubMed ID: 21699786
    [Abstract] [Full Text] [Related]

  • 9. Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C.
    Buti M, Agarwal K, Horsmans Y, Sievert W, Janczewska E, Zeuzem S, Nyberg L, Brown RS, Hézode C, Rizzetto M, Paraná R, De Meyer S, De Masi R, Luo D, Bertelsen K, Witek J.
    Gastroenterology; 2014 Mar 30; 146(3):744-753.e3. PubMed ID: 24316262
    [Abstract] [Full Text] [Related]

  • 10. Telaprevir for previously untreated chronic hepatitis C virus infection.
    Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S, ADVANCE Study Team.
    N Engl J Med; 2011 Jun 23; 364(25):2405-16. PubMed ID: 21696307
    [Abstract] [Full Text] [Related]

  • 11. Telaprevir for retreatment of HCV infection.
    Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, Müllhaupt B, Pockros P, Terg R, Shouval D, van Hoek B, Weiland O, Van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Polo R, Picchio G, Beumont M, REALIZE Study Team.
    N Engl J Med; 2011 Jun 23; 364(25):2417-28. PubMed ID: 21696308
    [Abstract] [Full Text] [Related]

  • 12. Antiviral effects of peginterferon alpha-2b and ribavirin following 24-week monotherapy of telaprevir in Japanese hepatitis C patients.
    Ozeki I, Akaike J, Karino Y, Arakawa T, Kuwata Y, Ohmura T, Sato T, Kamiya N, Yamada I, Chayama K, Kumada H, Toyota J.
    J Gastroenterol; 2011 Jul 23; 46(7):929-37. PubMed ID: 21556829
    [Abstract] [Full Text] [Related]

  • 13. Telaprevir activity in treatment-naive patients infected hepatitis C virus genotype 4: a randomized trial.
    Benhamou Y, Moussalli J, Ratziu V, Lebray P, De Backer K, De Meyer S, Ghys A, Luo D, Picchio GR, Beumont M.
    J Infect Dis; 2013 Sep 23; 208(6):1000-7. PubMed ID: 23801602
    [Abstract] [Full Text] [Related]

  • 14. Overview of the PROVE studies evaluating the use of telaprevir in chronic hepatitis C genotype 1 patients.
    Burney T, Dusheiko G.
    Expert Rev Anti Infect Ther; 2011 Feb 23; 9(2):151-60. PubMed ID: 21143041
    [Abstract] [Full Text] [Related]

  • 15. Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial.
    Reddy KR, Zeuzem S, Zoulim F, Weiland O, Horban A, Stanciu C, Villamil FG, Andreone P, George J, Dammers E, Fu M, Kurland D, Lenz O, Ouwerkerk-Mahadevan S, Verbinnen T, Scott J, Jessner W.
    Lancet Infect Dis; 2015 Jan 23; 15(1):27-35. PubMed ID: 25482330
    [Abstract] [Full Text] [Related]

  • 16. Non-invasive fibrosis assessment predicts sustained virological response to telaprevir with pegylated interferon and ribavirin for chronic hepatitis C.
    Ogawa E, Furusyo N, Shimizu M, Ihara T, Hayashi T, Harada Y, Toyoda K, Murata M, Hayashi J.
    Antivir Ther; 2015 Jan 23; 20(2):185-92. PubMed ID: 24941012
    [Abstract] [Full Text] [Related]

  • 17. [Safety and efficacy of telaprevir in patients with HIV and hepatitis C virus coinfection].
    Macías J, Rivero A.
    Enferm Infecc Microbiol Clin; 2013 Jul 23; 31 Suppl 3():33-6. PubMed ID: 24063901
    [Abstract] [Full Text] [Related]

  • 18. Adjusting the starting dose of telaprevir according to renal function decreases adverse effects and affects the sustained virological response rate.
    Morihara D, Watanabe H, Takata K, Iwashita H, Tsuchiya N, Kunimoto H, Kuno S, Fukunaga A, Yotsumoto K, Tanaka T, Sakurai K, Hirano G, Yokoyama K, Nishizawa S, Yoshikane M, Anan A, Takeyama Y, Kitamura Y, Iwata K, Irie M, Shakado S, Sohda T, Sakisaka S.
    Eur J Gastroenterol Hepatol; 2015 Jan 23; 27(1):55-64. PubMed ID: 25370853
    [Abstract] [Full Text] [Related]

  • 19. Effectiveness of triple therapy with simeprevir for chronic hepatitis C genotype 1b patients with prior telaprevir failure.
    Ogawa E, Furusyo N, Dohmen K, Kajiwara E, Kawano A, Nomura H, Takahashi K, Satoh T, Azuma K, Nakamuta M, Koyanagi T, Kotoh K, Shimoda S, Hayashi J, Kyushu University Liver Disease Study (KULDS) Group.
    J Viral Hepat; 2015 Dec 23; 22(12):992-1001. PubMed ID: 26075320
    [Abstract] [Full Text] [Related]

  • 20. Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial.
    Liu CH, Liu CJ, Huang CF, Lin JW, Dai CY, Liang CC, Huang JF, Hung PH, Tsai HB, Tsai MK, Lee CY, Chen SI, Yang SS, Su TH, Yang HC, Chen PJ, Chen DS, Chuang WL, Yu ML, Kao JH.
    Gut; 2015 Feb 23; 64(2):303-11. PubMed ID: 24747867
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.